GET DAILY SIGNALSStoke Therapeutics (STOK) Reports Wider Q3 Loss While Building Toward Phase 3 Readout
Key Takeaways
- Stoke Therapeutics reported a Q3 2026 net loss of $73.6 million, or $1.08 per share, compared with a loss of $38.3 million, or $0.65 per share, a year earlier.
- Quarterly revenue rose to $11.3 million from $10.6 million a year ago, topping the consensus estimate of roughly $8.21 million, while the per-share loss missed the consensus estimate of about -$0.93.
- Rising spending was driven by the advancement of zorevunersen, the company's investigational medicine for Dravet syndrome, including its Phase 3 EMPEROR study.
- The company held $358.8 million in cash, cash equivalents, and marketable securities as of September 30, 2026, which it expects to fund operations into early 2028.
- Management reaffirmed a Phase 3 data readout anticipated in the third quarter of 2027, followed by a planned U.S. NDA (New Drug Application) submission in the second half of 2027.
- For additional context on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
- Explore Trending AI Robots for AI-driven trading ideas and market insights.
Why This Quarter Matters for STOK
Stoke Therapeutics is a clinical-stage biotechnology company focused on RNA-based medicines, with its lead candidate zorevunersen targeting Dravet syndrome, a severe genetic epilepsy. Because the company generates most of its revenue from collaboration and licensing agreements rather than product sales, investors focus less on the top line and more on clinical progress, cash runway, and spending discipline. This quarter's results matter because they arrive as the Phase 3 EMPEROR trial moves toward a pivotal readout. Rising research and development (R&D) and launch-readiness costs underscore the company's transition toward a potential first regulatory approval, making the balance sheet and trial milestones the central considerations for shareholders. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Quarter's Reported Figures
For the three months ended September 30, 2026, Stoke Therapeutics recognized revenue of $11.3 million, up from $10.6 million in the same period of 2025. The revenue reflects satisfaction of contractual obligations under collaboration and licensing agreements with Acadia and Biogen.
The company posted a net loss of $73.6 million, or $1.08 per share, compared with a net loss of $38.3 million, or $0.65 per share, a year earlier. The wider loss was driven by higher operating expenses. R&D expenses climbed to $59.8 million from $37.7 million, while selling, general and administrative (SG&A) expenses rose to $28.7 million from $16.0 million, reflecting increased personnel and launch-readiness spending.
Against consensus, the per-share loss of -$1.08 was wider than the roughly -$0.93 analysts expected, while revenue of $11.25 million beat the consensus estimate of approximately $8.21 million. On a year-to-date basis, revenue fell to $26.8 million from $183.0 million, primarily because the prior-year period included recognition of a $150.8 million Biogen intellectual property license obligation. The nine-month net loss was $185.3 million, or $2.81 per share, versus net income of $51.0 million a year earlier.
Market Reaction and Investor Focus
Investor attention around STOK remains anchored to the zorevunersen program rather than quarterly revenue, which is collaboration-driven and can fluctuate significantly. The wider-than-expected per-share loss reflects a deliberate increase in investment ahead of the Phase 3 EMPEROR readout, and the company's cash position, expected to fund operations into early 2028, provides runway beyond the anticipated data milestone. Sentiment heading into the quarter was already shaped by the trial's enrollment completion and the company's plan to use a multi-component Vineland-3 assessment for its U.S. regulatory filing. The results themselves are likely to be interpreted primarily through the lens of execution risk and spending trajectory as the pivotal data event approaches.
Key Items to Monitor Ahead
The most important catalyst for Stoke Therapeutics remains the Phase 3 EMPEROR study of zorevunersen. Management expects a data readout in the third quarter of 2027, followed by a planned U.S. NDA submission to the U.S. Food and Drug Administration (FDA) in the second half of 2027.
Investors should watch for updates on the trial's primary endpoint, the change in major motor seizure frequency, as well as the key secondary endpoint measuring changes in cognition and behavior. The company's decision to use a multi-component assessment of four Vineland-3 subdomains for the regulatory filing is a notable development that may shape how the data are evaluated.
On the financial side, cost trends will remain in focus. R&D and SG&A expenses have risen materially year over year, and continued spending on launch readiness could keep operating losses elevated. The cash balance of $358.8 million, expected to support operations into early 2028, provides a financial cushion through the readout, but investors will monitor any changes to that runway guidance.
Finally, broader industry dynamics in rare-disease and neurology drug development, including regulatory expectations and competitive positioning in Dravet syndrome treatment, will be worth tracking as the company moves toward a potential first approval.
My Experience with Tickeron’s AI Tools
I often turn to Tickeron’s AI-powered tools when evaluating clinical-stage names like this one. The AI Screener lets me quickly filter for comparable biotech opportunities based on fundamentals, volatility, and technical signals, which helps put spending trends and cash runway into broader context without spending hours on manual screens. It has become a regular part of how I cross-check ideas before focusing on specific catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
STOK in upward trend: price may jump up because it broke its lower Bollinger Band on October 13, 2026
STOK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 28 cases where STOK's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where STOK's RSI Oscillator exited the oversold zone, 24 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on STOK as a result. In 64 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for STOK just turned positive on October 15, 2026. Looking at past instances where STOK's MACD turned positive, the stock continued to rise in 38 of 49 cases over the following month. The odds of a continued upward trend are 78%.
Following a +3.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where STOK advanced for three days, in 270 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STOK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for STOK entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.909) is normal, around the industry mean (3.154). P/E Ratio (-7.755) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (63.291) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. STOK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STOK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the research and development of treatments for genetic diseases.
Industry Biotechnology
Advertisement